The combination of low dose BTZ (10 nM) and siMDM2 (10 nM) significantly impaired MM1.R and 8226R5 cell viability, whereas the exposure to siRNA or drug alone did not significantly impair MM cell viability (Figure 2B). The gene discussed is CASC3; the disease is Miyoshi myopathy.